Corona-Drug: Remdesivir receives European approval for Covid-19

admitted to the Particular well known now in Europe, too, officially: The active ingredient Remdesivir, the severe gradients of the Covid-19-the disease is to r

Corona-Drug: Remdesivir receives European approval for Covid-19

admitted to the Particular well known now in Europe, too, officially: The active ingredient Remdesivir, the severe gradients of the Covid-19-the disease is to relieve, can now be used in European hospitals. The decision, the EU Commission announced on Friday. "Today's approval of the first drug for the treatment of Covid-19 is an important step forward in the fight against the Virus," said health Commissioner Stella Kyriakides. The approval was issued in less than a month after the request.

Remdesivir is considered to be one of the few effective agents in severe cases of the Coronavirus-induced lung disease. It can be shorten according to studies, the hospital stay. The European medicines Agency EMA recommended the marketing authorisation for patients aged twelve years, a pneumonia, and supplemental oxygen must be supplied.

Doctors Remdesivir not be seen as panacea, but as a beacon of light for Corona-patients. An international study with over 1000 participants has shown at the end of April, that Remdesivir at Covid-19-patients can shorten the time to recovery in an average of four days - from 15 to 11 days.

The United States had already been issued at the beginning of may a derogation for the limited use of the drug in hospitals. In Germany, too, the Mediterranean was already within a compassionate use program is accessible and has been tested in clinical trials.

the negotiations in an early stage

The American government had made this week an agreement with the American manufacturer Gilead Sciences announced it has practically buys the whole production amount of By means of for the next few months. However, it has created, for example, Germany, already supplies. An EU Commission spokesman said it is negotiating with the manufacturer, a reservation of a sufficient number of treatment doses of the Agent. The negotiations are at an early stage. On the quantity and the cost he wanted to say anything.

The CDU-Europe politician Peter Liese stressed that a condition for the approval in Europe is that the manufacturer will deliver to Europe. A possible solution for the bottlenecks would be, that Gilead share his knowledge with other producers, and this leave against license fees produce. Also, so that Gilead could earn a lot of money, said Liese on Friday.

Updated Date: 03 July 2020, 08:19

You need to login to comment.

Please register or login.

RELATED NEWS